Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJP-0132 in Dry Eye Disease
NCT04139122Phase 2Completed
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Oct 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of motsugibatorep in dry eye disease (DED) (4 cohorts), sponsored by Senju Pharmaceutical Co., Ltd. Primary endpoints: Number of Participants With Adverse Events by Severity at Day 29, Number of Subjects With Abnormal Changes in Laboratory Parameters, Vital Signs, and/or Physical and Ophthalmologic Observations at Day 29 and 5 more. Started Oct 2019; status: completed.
02
Drugs
motsugibatorep
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04139122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04139122.